Angiotensin Ii

Concomitant use with ARBs in diabetic patients is contraindicated. In non-diabetics, generally avoid combined use, especially with CrCl <60 mL/min, due to increased risk of hypotension, hyperkalemia, and acute renal failure.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid concomitant use.

Risk of hyperkalemia may be increased when amiloride HCl is administered concomitantly. Use with caution and frequent monitoring of serum potassium.

Dual blockade of RAS with valsartan and other ARBs is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.

Use to control hypertension has been reported to induce anemia and severe leukopenia in patients on azathioprine.

Dual RAS blockade with other angiotensin receptor blockers increases risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.

Dual RAS blockade associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.

Dual RAS blockade associated with increased risks of hyperkalemia, hypertension, and acute renal failure. Avoid combined use.

Dual blockade of the RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure. Monitor blood pressure, renal function and electrolytes closely.

Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.

Concomitant administration can lead to severe hyperkalemia. Check serum potassium levels when ARB therapy is altered.

May diminish antihypertensive effect; in elderly, volume depleted, or renally impaired patients may result in deterioration of renal function.

Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly with other hyperkalemia risk factors.

May diminish antihypertensive effect and result in renal function deterioration in vulnerable patients.

May result in deterioration of renal function including possible acute renal failure in elderly, volume-depleted, or renally impaired patients. NSAIDs may diminish antihypertensive effect.

Dual blockade of RAS increases risk of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.

Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.

Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.

Combination increases risk of hyperkalemia. Monitor serum potassium and renal function closely, especially in elderly or those with impaired renal function.

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function.

May lead to severe hypotension and deterioration in renal function, including renal failure.

May lead to severe hypotension and deterioration in renal function, including renal failure. Monitor blood pressure and renal function; adjust dosage if needed.

Furosemide combined with ACE inhibitors may lead to severe hypotension and deterioration in renal function, including renal failure.

May result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. May diminish antihypertensive effect.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Dual blockade of the RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure. Avoid combined use.

Dual RAS blockade increases risk of hypotension, hyperkalemia, and acute renal failure. Combined use should generally be avoided.

Concomitant use may increase the risk for anaphylactic-type reactions to iron dextran product.

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.

Dual blockade of the RAS with angiotensin receptor blockers and lisinopril is associated with increased risk of hypotension, hyperkalemia, and changes in renal function including acute renal failure.

Concomitant use increases steady-state serum lithium concentrations.

Concomitant use increases steady-state serum lithium concentrations, requiring frequent monitoring and dosage adjustment.

Dual blockade of the renin-angiotensin system is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function including acute renal failure.

NSAIDs may diminish antihypertensive effects and result in renal function deterioration or acute renal failure in elderly, volume-depleted, or renally impaired patients.

Dual RAS blockade is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.

Dual blockade with ACE inhibitors is associated with increased risks of hypotension, hyperkalemia, and changes in renal function. Most patients do not obtain additional benefit compared to monotherapy.

Agonistic effects increase phenylephrine blood pressure effect.

Concurrent use may lead to serious hyperkalemia. Combination requires careful monitoring.

Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other hyperkalemia risk factors.

Increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other risk factors. Avoid use if possible.

ACE inhibitors may increase serum potassium levels when used with potassium chloride, potentially leading to hyperkalemia.

RAAS inhibitors that produce potassium retention; monitor for hyperkalemia with concomitant use.

Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly with other hyperkalemia risk factors.

Produce potassium retention by inhibiting aldosterone production; closely monitor potassium levels.

Concurrent use may result in hyperkalemia and cardiac arrhythmias or cardiac arrest.

Concomitant use may enhance the pressor response and increase the risk of hypertension.

Avoid concomitant use as sacubitril and valsartan contains valsartan, an angiotensin II receptor blocker.

Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.

Angiotensin II receptor antagonists increase hyperkalemia risk; avoid use due to potassium content or monitor serum potassium concentrations.

ARBs can increase serum potassium; concomitant use with spironolactone may lead to severe hyperkalemia. Check potassium levels when therapy is altered.

Concomitant administration may lead to severe hyperkalemia.

Three cases of hyperkalemia in elderly patients reported after concomitant intake of sulfamethoxazole and trimethoprim and ACE inhibitors.

NSAIDs may diminish antihypertensive effect and cause further deterioration of renal function, including possible acute renal failure in patients with compromised renal function.

Dual blockade of renin-angiotensin system associated with increased risks of hypotension, hyperkalemia, and renal impairment without additional cardiovascular benefit.

Increased risk of hypotension and renal impairment when used concomitantly with torsemide.

Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.

Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.

Potassium-sparing diuretics with ACE inhibitors increase risk of hyperkalemia. Use with caution.

Greatly increased risk of hyperkalemia when potassium-sparing agents are used with ACE inhibitors. Serum potassium should be monitored frequently.

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.

Concomitant angiotensin-converting enzyme inhibitors may increase the risk of angioedema, particularly in patients with acute ischemic stroke.

Risk of hyperkalemia may be increased when used concomitantly with amiloride HCl. Requires caution and frequent monitoring of serum potassium.

NSAIDs may diminish antihypertensive effect and may result in deterioration of renal function, especially in elderly, volume-depleted, or renally impaired patients.

Diclofenac may diminish antihypertensive effect and cause renal function deterioration in elderly, volume-depleted, or renal-impaired patients.

NSAIDs may diminish antihypertensive effect and may result in deterioration of renal function or acute renal failure in elderly, volume-depleted, or renally impaired patients.

NSAIDs may diminish antihypertensive effect. In elderly, volume-depleted, or renally impaired patients, may result in deterioration of renal function including acute renal failure.

When administered concomitantly, patients should be adequately hydrated and renal function assessed at baseline.

NSAIDs may diminish antihypertensive effect; in elderly, volume-depleted, or renally impaired patients, may cause renal function deterioration including acute renal failure.

May diminish antihypertensive effect; in elderly, volume-depleted, or renal impairment patients may result in deterioration of renal function.

NSAIDs may diminish antihypertensive effect and can cause renal impairment in elderly, volume-depleted, or renally impaired patients.

NSAIDs may diminish the antihypertensive effect of angiotensin II antagonists. Co-administration may result in further deterioration of renal function, including possible acute renal failure in patients with compromised renal function.

May impair digoxin excretion by declining GFR or tubular secretion. Monitor renal function and digoxin levels.

May increase serum potassium concentration when used with drospirenone.

Potential for increased serum potassium when drospirenone is used with angiotensin receptor blockers, more pronounced in diabetic women.

NSAIDs may diminish antihypertensive effect; renal function deterioration possible in elderly, volume-depleted, or renally impaired patients.

May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Angiotensin II receptor antagonists may increase risk of hyperkalemia when used with CLINIMIX E due to its potassium content; administer with caution.

Concomitant use increases steady-state serum lithium concentrations. Recommend frequent monitoring and dosage adjustment.

Antihypertensives; small reductions in blood pressure occur following coadministration with tadalafil.

NSAIDs may diminish the antihypertensive effect of angiotensin receptor blockers.

NSAIDs may diminish the antihypertensive effect of angiotensin receptor blockers.

May diminish antihypertensive effect and in elderly, volume depleted, or renally impaired patients may result in renal function deterioration.

ACE inhibitors increase risk of fluid and electrolyte abnormalities when used with this drug combination. Use caution and consider additional patient evaluations.

May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution.

Avoid use due to potassium content increasing risk of hyperkalemia. If unavoidable, monitor serum potassium concentrations.

Small reductions in blood pressure occurred following coadministration of tadalafil compared with placebo.

Concomitant use increases hyperkalemia risk by approximately 1-2%. Serum potassium levels should be monitored.